These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Financing vaccines: in search of solutions that work. Iglehart JK Health Aff (Millwood); 2005; 24(3):594-5. PubMed ID: 15886147 [No Abstract] [Full Text] [Related]
23. Developing countries take a creative approach to R&D. Fleck F Bull World Health Organ; 2005 Jan; 83(1):4-5. PubMed ID: 15682239 [No Abstract] [Full Text] [Related]
24. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. Kesselheim AS Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908 [No Abstract] [Full Text] [Related]
25. The introduction of new vaccines into developing countries. IV: Global Access Strategies. Mahoney RT; Krattiger A; Clemens JD; Curtiss R Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119 [TBL] [Abstract][Full Text] [Related]
26. GAVI and the Vaccine Fund--a boon for immunization in the developing world. Balaji KA Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583 [TBL] [Abstract][Full Text] [Related]
27. Plea to restore public funding for vaccine development. Puliyel JM Lancet; 2004 Feb; 363(9409):659. PubMed ID: 14987898 [No Abstract] [Full Text] [Related]
28. The costs and economics of modern vaccine development. Batson A Dev Biol (Basel); 2002; 110():15-24. PubMed ID: 12477302 [No Abstract] [Full Text] [Related]
29. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
30. Research on hire. Gupta AS Issues Med Ethics; 2001; 9(4):111-3. PubMed ID: 16334912 [No Abstract] [Full Text] [Related]
31. Are advance market commitments for drugs a real advance? Scudellari M Nat Med; 2011 Feb; 17(2):139. PubMed ID: 21297588 [No Abstract] [Full Text] [Related]
32. Government financing for health and specific national budget lines: the case of vaccines and immunization. Lydon P; Beyai PL; Chaudhri I; Cakmak N; Satoulou A; Dumolard L Vaccine; 2008 Dec; 26(51):6727-34. PubMed ID: 18625279 [TBL] [Abstract][Full Text] [Related]
33. Drugs and vaccines around the world. Health Aff (Millwood); 2006; 25(2):312. PubMed ID: 16522572 [No Abstract] [Full Text] [Related]
34. [Drug industry in India is threatened by free trade agreement]. Jeppsson A Lakartidningen; 2009 Oct 7-13; 106(41):2589. PubMed ID: 19927922 [No Abstract] [Full Text] [Related]
35. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. Patel MM; Parashar UD J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612 [TBL] [Abstract][Full Text] [Related]
36. India will supply coronavirus vaccines to the world - will its people benefit? Vaidyanathan G Nature; 2020 Sep; 585(7824):167-168. PubMed ID: 32884143 [No Abstract] [Full Text] [Related]
37. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Jadhav S; Datla M; Kreeftenberg H; Hendriks J Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742 [TBL] [Abstract][Full Text] [Related]
38. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association. Tan L; Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133 [TBL] [Abstract][Full Text] [Related]